The AMR Industry Alliance Gains a New Member as Recipharm Joins

Article

Forming part of its ambition to contribute to the fight against AMR, Recipharm has announced that it is joining the AMR Industry Alliance, which is one of the largest coalitions set up to provide sustainable solutions to the growing problem of AMR.

Forming part of its ambition to contribute to the fight against antimicrobial resistance (AMR), Recipharm has announced that it is joining the AMR Industry Alliance, which is one of the largest coalitions set up to provide sustainable solutions to the growing problem of AMR.

In a Nov. 14, 2019 press release, Recipharm revealed that its decision to join the AMR Industry Alliance, which includes more than 100 members, is part of its ongoing efforts to engage with other organizations toward solutions to combat AMR. Another initiative that Recipharm is involved with that has a focus on AMR is the multisector collaboration platform, PLATINEA, which is led by Uppsala University.

“AMR is currently one of the most serious health concerns worldwide. At Recipharm, we manufacture antibiotics in Sweden, Italy, and India so it’s important that we get involved in developing solutions to combat AMR,” said Erik Haeffler, vice-president of manufacturing services and head of sustainability at Recipharm, in the press release. “Joining the AMR Industry Alliance was the next natural step for us to take our work on AMR to the next level and allow us to engage with other stakeholders on the subject.”

“We welcome Recipharm as a new member of the alliance,” added Steve Brooks, chair of the Manufacturing Working Group at the AMR Industry Alliance. “In recent years, we’ve seen more and more companies recognizing and addressing AMR, and we’re delighted to see a leading CDMO [contract development and manufacturing organization] like Recipharm committing to the objectives of the AMR Industry Alliance, including minimizing antibiotic emissions from the manufacturing supply chain.”

Source: Recipharm

 

Recent Videos
Behind the Headlines episode 6
CPHI Milan 2024: Highlighting the Benefits of Integrated Services
Behind the Headlines episode 5
Buy, Sell, Hold: Cell and Gene Therapy
Buy, Sell, Hold: Cell and Gene Therapy
Buy, Sell, Hold: Cell and Gene Therapy
Related Content